Spur Therapeutics
London, United Kingdom
Program data pending ClinicalTrials.gov matching
55.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
Quick Facts: Spur Therapeutics
- Signal Score
- 55.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- London, United Kingdom
- Modalities
- AAV Gene Therapy
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Spur Therapeutics
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAAV Gene Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
50.0
Manufacturing site information being gathered
Modalities: AAV Gene Therapy
Capacity assessment: 50.0/100
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press10 articles
Manufacturing site information being gathered
Modalities: AAV Gene Therapy
Capacity assessment: 50.0/100
Recent News 10 articles
Around the Helix: Cell and Gene Therapy Company Updates – February 4, 2026 - CGTLive®
Freeline and SwanBio join forces to create Spur Therapeutics - Manufacturing Chemist
Spur Therapeutics to begin Phase III gene therapy trial in Gaucher disease - Clinical Trials Arena
Montco gene therapy developer SwanBio acquired by London firm - The Business Journals
Patients Treated With Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Maintain Clinical Benefit for Up to 2 Years - CGTLive®
One-time gene therapy controls Gaucher disease symptoms - Gaucher Disease News
Syncona melds two gene therapy biotechs for better shot at new nervous system treatments - BioPharma Dive
Freeline Therapeutics Rebrands to Spur Therapeutics - Contract Pharma
Syncona merges Freeline and SwanBio to spur new gene-therapy-focused biotech - Fierce Biotech
Gene therapy may improve bone health in Gaucher disease - Gaucher Disease News
Frequently Asked Questions About Spur Therapeutics
What is Spur Therapeutics's CDMO Signal Score?
Spur Therapeutics has a Signal Score of 55/100, based on quality, operations, financial stability, and capacity data.
Evaluating Spur Therapeutics for a manufacturing program?
Use the free AI matchmaker to compare Spur Therapeutics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: